Amyloid deposition occurs in aging, even in individuals free from cognitive symptoms, and is often interpreted as preclinical Alzheimer’s disease (AD) pathophysiology. YKL-40 is a marker of neuroinflammation, being increased in AD, and hypothesized to interact with amyloid-β (Aβ) in causing cognitive decline early in the cascade of AD pathophysiology. Whether and how Aβ and YKL-40 affect brain and cognitive changes in cognitively healthy older adults is still unknown. We studied 89 participants (mean age: 73.1 years) with cerebrospinal fluid samples at baseline, and both MRI and cognitive assessments from two time-points separated by two years. We tested how baseline levels of Aβ42 and YKL-40 correlated with changes in cortical thickness and cognition. Thickness change correlated with Aβ42 only in Aβ42+ participants (<600 pg/mL, n = 27) in the left motor and premotor cortices. Aβ42 was unrelated to cognitive change. Increased YKL-40 was associated with less preservation of scores on the animal naming test in the total sample (r = –0.28, p = 0.012) and less preservation of a score reflecting global cognitive function for Aβ42+ participants (r = –0.58, p = 0.004). Our results suggest a role for inflammation in brain atrophy and cognitive changes in cognitively normal older adults, which partly depended on Aβ accumulation.
BlennowK, HampelH, WeinerM, ZetterbergH (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol6, 131–144.
2.
MorminoEC (2014) The relevance of beta-amyloid on markers of Alzheimer’s disease in clinically normal individuals and factors that influence these associations. Neuropsychol Rev24, 300–312.
ChételatG, OssenkoppeleR, VillemagneVL, PerrotinA, LandeauB, MézengeF, JagustWJ, DoreV, MillerBL, EgretS, SeeleyWW, van der FlierWM, La JoieR, AmesD, van BerckelBNM, ScheltensP, BarkhofF, RoweCC, MastersCL, de La SayetteV, BouwmanF, RabinoviciGD (2016) Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer’s disease. Brain139(Pt 9), 2528–2539.
5.
FleischmanDA, ArfanakisK, KellyJF, RajendranN, BuchmanAS, MorrisMC, BarnesLL, BennettDA (2010) Regional brain cortical thinning and systemic inflammation in older persons without dementia. J Am Geriatr Soc58, 1823–1825.
RosénC, AnderssonC-H, AndreassonU, MolinuevoJL, BjerkeM, RamiL, LladóA, BlennowK, ZetterbergH (2014) Increased levels of chitotriosidase and YKL-40 in cerebrospinal fluid from patients with Alzheimer’s disease. Dement Geriatr Cogn Dis Extra4, 297–304.
12.
AntonellA, MansillaA, RamiL, LladóA, IranzoA, OlivesJ, BalasaM, Sánchez-ValleR, MolinuevoJL (2014) Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer’s disease. J Alzheimers Dis42, 901–908.
13.
JanelidzeS, HertzeJ, ZetterbergH, LandqvistWaldö M, SantilloA, BlennowK, HanssonO (2016) Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer’s disease. Ann Clin Transl Neurol3, 12–20.
14.
AlcoleaD, VilaplanaE, PeguerolesJ, MontalV, Sánchez-JuanP, González-SuárezA, PozuetaA, Rodríguez-RodríguezE, Bartrés-FazD, Vidal-PiñeiroD, González-OrtizS, MedranoS, Carmona-IraguiM, Sánchez-SaudinósM, SalaI, Anton-AguirreS, SampedroF, Morenas-RodríguezE, ClarimónJ, BlesaR, LleóA, ForteaJ (2015) Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer’s disease. Neurobiol Aging36, 2018–2023.
15.
GispertJD, MontéGC, FalconC, TucholkaA, RojasS, Sánchez-ValleR, AntonellA, LladóA, RamiL, MolinuevoJL (2016) CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. Neurobiol Aging38, 47–55.
16.
OlssonB, LautnerR, AndreassonU, ÖhrfeltA, PorteliusE, BjerkeM, HölttäM, RosénC, OlssonC, StrobelG, WuE, DakinK, PetzoldM, BlennowK, ZetterbergH (2016) CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis. Lancet Neurol15, 673–684.
17.
HellwigK, KvartsbergH, PorteliusE, AndreassonU, ObersteinTJ, LewczukP, BlennowK, KornhuberJ, MalerJM, ZetterbergH, SpitzerP (2015) Neurogranin and YKL-40: Independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease. Alzheimers Res Ther7, 74.
18.
MattssonN, TabatabaeiS, JohanssonP, HanssonO, AndreassonU, MånssonJ-E, JohanssonJ-O, OlssonB, WallinA, SvenssonJ, BlennowK, ZetterbergH (2011) Cerebrospinal fluid microglial markers in Alzheimer’sdisease: Elevated chitotriosidase activity but lack of diagnostic utility. Neuromolecular Med13, 151–159.
19.
FaganAM, HeadD, ShahAR, MarcusD, MintunM, MorrisJC, HoltzmanDM (2009) Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol65, 176–183.
20.
SchottJM, BartlettJW, FoxNC, BarnesJ, Alzheimer’s Disease Neuroimaging Initiative Investigators (2010) Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1-42. Ann Neurol68, 825–834.
21.
TosunD, SchuffN, Truran-SacreyD, ShawLM, TrojanowskiJQ, AisenP, PetersonR, WeinerMW (2010) Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: A longitudinal MRI study. Neurobiol Aging31, 1340–1354.
22.
ChételatG, VillemagneVL, PikeKE, BaronJ-C, BourgeatP, JonesG, FauxNG, EllisKA, SalvadoO, SzoekeC, MartinsRN, AmesD, MastersCL, RoweCC (2010) Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain133, 3349–3358.
BeckerJA, HeddenT, CarmasinJ, MayeJ, RentzDM, PutchaD, FischlB, GreveDN, MarshallGA, SallowayS, MarksD, BucknerRL, SperlingRA, JohnsonKA (2011) Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol69, 1032–1042.
25.
FjellAM, WalhovdKB, Fennema-NotestineC, McEvoyLK, HaglerDJ, HollandD, BlennowK, BrewerJB, DaleAM, Alzheimer’s Disease Neuroimaging Initiative (2010) Brain atrophy in healthy aging is related to CSF levels of Aβ1-42. Cereb Cortex20, 2069–2079.
26.
HeddenT, OhH, YoungerAP, PatelTA (2013) Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology80, 1341–1348.
27.
MorrisJC, HeymanA, MohsRC, HughesJP, van BelleG, FillenbaumG, MellitsED, ClarkC (1989) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology39, 1159–1165.
28.
SpreenO, StraussE (1991) A compendium of neuropsychological tests: Administration, norms, and commentary, Oxford University Press, New York.
29.
ReitanRM (1955) The relation of the trail making test to organic brain damage. J Consult Psychol19, 393–394.
30.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
31.
ShulmanKI (2000) Clock-drawing: Is it the ideal cognitive screening test?Int J Geriatr Psychiatry15, 548–561.
SmithEE, SalatDH, JengJ, McCrearyCR, FischlB, SchmahmannJD, DickersonBC, ViswanathanA, AlbertMS, BlackerD, GreenbergSM (2011) Correlations between MRI white matter lesion location and executive function and episodic memory. Neurology76, 1492–1499.
39.
OlssonE, KlassonN, BergeJ, EckerströmC, EdmanA, MalmgrenH, WallinA, MalmgrenH, WallinA (2013) White matter lesion assessment in patients with cognitive impairment and healthy controls: Reliability comparisons between visual rating, a manual, and an automatic volumetrical MRI method-the Gothenburg MCI study. J Aging Res2013, 198471.
40.
MulderC, VerweyNA, van der FlierWM, BouwmanFH, KokA, van ElkEJ, ScheltensP, BlankensteinMA (2010) Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem56, 248–253.
41.
NiemantsverdrietE, GoossensJ, StruyfsH, MartinJ-J, GoemanJ, De DeynPP, VandersticheleH, EngelborghsS (2016) Diagnostic impact of cerebrospinal fluid biomarker (pre-)analytical variability in Alzheimer’s disease. J Alzheimers Dis51, 97–106.
42.
ZwanMD, RinneJO, HasselbalchSG, NordbergA, LleóA, HerukkaS-K, SoininenH, LawI, BahlJMC, CarterSF, ForteaJ, BlesaR, TeunissenCE, BouwmanFH, van BerckelBNM, VisserPJ (2016) Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study. Neurology86, 50–58.
43.
PalmqvistS, ZetterbergH, BlennowK, VestbergS, AndreassonU, BrooksDJ, OweniusR, HägerströmD, WollmerP, MinthonL, HanssonO (2014) Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: A cross-validation study against amyloid positron emission tomography. JAMA Neurol71, 1282–1289.
44.
HaglerDJ, SayginAP, SerenoMI (2006) Smoothing and cluster thresholding for cortical surface-based group analysis of fMRI data. Neuroimage33, 1093–1103.
45.
GalvinJE, PowlishtaKK, WilkinsK, McKeelDW, XiongC, GrantE, StorandtM, MorrisJC (2005) Predictors of preclinical Alzheimer disease and dementia: A clinicopathologic study. Arch Neurol62, 758–765.
46.
DamoiseauxJS, BeckmannCF, ArigitaEJ, BarkhofF, ScheltensP, StamCJ, SmithSM, RomboutsSA (2008) Reduced resting-state brain activity in the “default network” in normal aging. Cereb Cortex18, 1856–1864.
47.
FjellAM, McEvoyL, HollandD, DaleAM, WalhovdKB (2014) What is normal in normal aging? Effects of aging, amyloid and Alzheimer’s disease on the cerebral cortex and the hippocampus. Prog Neurobiol117, 20–40.
48.
BraakH, BraakE (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging18, 351–357.
49.
AschenbrennerAJ, BalotaDA, FaganAM, DuchekJM, BenzingerTLS, MorrisJC (2015) Alzheimer disease cerebrospinal fluid biomarkers moderate baseline differences and predict longitudinal change in attentional control and episodic memory composites in the Adult Children Study. J Int Neuropsychol Soc21, 573–583.
50.
FjellAM, McEvoyL, HollandD, DaleAM, WalhovdKB (2013) Brain changes in older adults at very low risk for Alzheimer’s disease. J Neurosci33, 8237–8242.
51.
PerssonN, GhislettaP, DahleCL, BenderAR, YangY, YuanP, DaughertyAM, RazN (2016) Regional brain shrinkage and change in cognitive performance over two years: The bidirectional influences of the brain and cognitive reserve factors. Neuroimage126, 15–26.
52.
RodrigueKM, RazN (2004) Shrinkage of the entorhinal cortex over five years predicts memory performance in healthy adults. J Neurosci24, 956–963.
53.
MelahKE, LuSY-F, HoscheidtSM, AlexanderAL, AdluruN, DesticheDJ, CarlssonCM, ZetterbergH, BlennowK, OkonkwoOC, GleasonCE, DowlingNM, BratzkeLC, RowleyHA, SagerMA, AsthanaS, JohnsonSC, BendlinBB (2015) Cerebrospinal fluid markers of Alzheimer’s disease pathology and microglial activation are associated with altered white matter microstructure in asymptomatic adults at risk for Alzheimer’s disease. J Alzheimers Dis50, 873–886.
54.
Arenaza-UrquijoEM, MolinuevoJ-L, Sala-LlonchR, Solé-PadullésC, BalasaM, BoschB, OlivesJ, AntonellA, LladóA, Sánchez-ValleR, RamiL, Bartrés-FazD (2013) Cognitive reserve proxies relate to gray matter loss in cognitively healthy elderly with abnormal cerebrospinal fluid amyloid-β levels. J Alzheimers Dis35, 715–726.
55.
GouwensLK, MakoniNJ, RogersVA, NicholsMR (2016) Amyloid-β42 protofibrils are internalized by microglia more extensively than monomers. Brain Res1648, 485–495.
